Summary
WPATH's Standards of Care 8 (2022) is the world's most influential guideline for transgender healthcare. In this study, eight trained raters, doctors and therapists from several fields plus two experienced guideline experts, scored six chapters relevant to young people using the standard checklist for judging how well guidelines are made. The chapters scored poorly on rigour (how evidence was searched for, chosen and linked to advice), on practical usefulness and on independence from funders and conflicts. Overall quality was rated about 3.5 to 4 out of 7. Raters split evenly between recommending the chapters, recommending them with changes, and rejecting them. The findings echo the Cass Review's earlier rating. The study was funded by SEGM, and only eight raters took part.
Key findings
- هشت ارزیاب شامل یک پزشک هورمون‌شناسی کودکان، جراح پلاستیک، پزشک کودکان، پزشک خانواده، روانشناس، روانپزشک و دو متخصص راهنما، هر کدام به طور مستقل شش فصل از راهنمای WPATH را امتیازدهی کردند.
- مراقبت در تدوین توصیه‌ها در فصول مختلف ۳۹ تا ۴۷ درصد امتیاز گرفت؛ نحوه جستجو و انتخاب شواهد تنها حدود ۱.۵ تا ۲.۵ از ۷ امتیاز کسب کرد.
- کاربردی بودن با کمترین امتیاز ۲۸ تا ۴۰ درصد بود و برنامه‌های بررسی چگونگی عملکرد توصیه‌ها در عمل، ۱ تا ۱.۵ از ۷ امتیاز دریافت کردند.
- استقلال ۴۳ تا ۴۴ درصد امتیاز گرفت، زیرا نحوه مدیریت تأثیر تأمین‌کنندگان مالی و تعارض منافع نامشخص بود.
- کیفیت کلی هر فصل (نوجوانان، کودکان، هورمون‌ها، سلامت روان، مراقبت پزشک خانواده و جراحی) حدود ۳.۵ تا ۴ از ۷ ارزیابی شد.
- تنها دو نفر از هشت ارزیاب فصول را بدون تغییر توصیه می‌کردند؛ سه نفر با تغییر و سه نفر دیگر اصلاً توصیه نمی‌کردند.
- منابع مالی: این مطالعه توسط SEGM تأمین مالی شد که به گفته نویسندگان، هیچ نقشی در طراحی، تحلیل یا نگارش آن نداشته است. نویسنده اصلی با SEGM مشورت کرده و به هر ارزیاب بالینی برای حدود ۳۰ تا ۴۰ ساعت کار، ۱۵۰۰ دلار آمریکا پرداخت شد. هیچ منبع مالی دیگری اعلام نشده است.
Abstract
In 2022, the World Professional Association for Transgender Health (WPATH) released their guidelines, Standards of Care Version 8 (SOC8), which have been regarded as establishing standards for the management of transgender patients. To conduct a quality assessment of the WPATH's SOC8 using the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument, we recruited a diverse group of international health professionals as assessors, including six clinicians and two guideline methodologists, who were trained in the AGREE II tool and underwent a calibration exercise. They independently assessed six SOC8 chapters: adolescents, children, hormone therapy, mental health, primary care, and surgery. We summarized the ratings across assessors for all items to present the strengths and limitations of the guidelines. The evaluations identified that the SOC8 chapters had limitations in the AGREE II domains of applicability (ranging from 28% to 40% across chapters), editorial independence (ranging from 43% to 44% across chapters), and rigor of development (ranging from 39% to 47% across chapters). On a scale of 1 to 7 (7 = highest quality), the median overall quality score was 3.5 to 4 for all chapters. Two of eight assessors recommended using the guideline chapters, while three recommended use with modification, and three recommended not to use the reviewed guideline chapters due to methodological concerns. Evidence-based guidelines addressing the needs of transidentified people are urgently needed, but it is imperative that healthcare providers, researchers, and policymakers recognize and address the limitations present in these six SOC8 chapters.
Conclusion
The assessment found that WPATH's SOC8 guidelines have limitations in scientific and methodological rigour, applicability, and transparency in managing competing interests. Evidence-based guidelines addressing the needs of trans-identified children and adolescents are urgently needed, but uncritical adoption or endorsement of WPATH's guidelines may result in a disservice or even harm to this vulnerable population. Healthcare providers, researchers and policymakers should recognise and address the limitations of SOC8.